ID   RYR2_MOUSE              Reviewed;        4966 AA.
AC   E9Q401; O70181; Q62174; Q62197; Q9ERN6;
DT   22-FEB-2012, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 1.
DT   22-FEB-2023, entry version 100.
DE   RecName: Full=Ryanodine receptor 2;
DE            Short=RYR-2;
DE            Short=RyR2;
DE   AltName: Full=Cardiac muscle ryanodine receptor;
DE   AltName: Full=Cardiac muscle ryanodine receptor-calcium release channel;
DE   AltName: Full=Type 2 ryanodine receptor;
GN   Name=Ryr2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   MUTAGENESIS OF GLY-4819; ARG-4821; GLY-4823; GLY-4824; GLY-4825; GLY-4827
RP   AND ASP-4828.
RX   PubMed=10473538; DOI=10.1074/jbc.274.37.25971;
RA   Zhao M., Li P., Li X., Zhang L., Winkfein R.J., Chen S.R.;
RT   "Molecular identification of the ryanodine receptor pore-forming segment.";
RL   J. Biol. Chem. 274:25971-25974(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16, FUNCTION, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=9628868; DOI=10.1093/emboj/17.12.3309;
RA   Takeshima H., Komazaki S., Hirose K., Nishi M., Noda T., Iino M.;
RT   "Embryonic lethality and abnormal cardiac myocytes in mice lacking
RT   ryanodine receptor type 2.";
RL   EMBO J. 17:3309-3316(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4145-4966, AND TISSUE SPECIFICITY.
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=7876312; DOI=10.1083/jcb.128.5.893;
RA   Giannini G., Conti A., Mammarella S., Scrobogna M., Sorrentino V.;
RT   "The ryanodine receptor/calcium channel genes are widely and differentially
RT   expressed in murine brain and peripheral tissues.";
RL   J. Cell Biol. 128:893-904(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4863-4966, AND TISSUE SPECIFICITY.
RC   STRAIN=C57BL/6J; TISSUE=Heart;
RX   PubMed=7621815; DOI=10.1002/j.1460-2075.1995.tb07302.x;
RA   Takeshima H., Yamazawa T., Ikemoto T., Takekura H., Nishi M., Noda T.,
RA   Iino M.;
RT   "Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the
RT   type-1 ryanodine receptor.";
RL   EMBO J. 14:2999-3006(1995).
RN   [6]
RP   PHOSPHORYLATION AT SER-2030.
RX   PubMed=17693412; DOI=10.1074/jbc.m703510200;
RA   Xiao B., Tian X., Xie W., Jones P.P., Cai S., Wang X., Jiang D., Kong H.,
RA   Zhang L., Chen K., Walsh M.P., Cheng H., Chen S.R.W.;
RT   "Functional consequence of protein kinase A-dependent phosphorylation of
RT   the cardiac ryanodine receptor: sensitization of store overload-induced
RT   Ca2+ release.";
RL   J. Biol. Chem. 282:30256-30264(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1341; SER-2368; SER-2796;
RP   SER-2807; SER-2810; SER-2813 AND SER-2946, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Heart, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT SER-2807 AND SER-2813, INTERACTION WITH
RP   FKBP1B, AND MUTAGENESIS OF SER-2813.
RX   PubMed=21098440; DOI=10.1161/circulationaha.110.982298;
RA   van Oort R.J., McCauley M.D., Dixit S.S., Pereira L., Yang Y.,
RA   Respress J.L., Wang Q., De Almeida A.C., Skapura D.G., Anderson M.E.,
RA   Bers D.M., Wehrens X.H.;
RT   "Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein
RT   kinase II promotes life-threatening ventricular arrhythmias in mice with
RT   heart failure.";
RL   Circulation 122:2669-2679(2010).
RN   [9]
RP   FUNCTION, INTERACTION WITH FKBP1A AND FKBP1B, AND PHOSPHORYLATION AT
RP   SER-2807.
RX   PubMed=20431056; DOI=10.1161/circresaha.110.219816;
RA   Guo T., Cornea R.L., Huke S., Camors E., Yang Y., Picht E., Fruen B.R.,
RA   Bers D.M.;
RT   "Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized
RT   cardiac myocytes and effects on Ca sparks.";
RL   Circ. Res. 106:1743-1752(2010).
RN   [10]
RP   REVIEW.
RX   PubMed=20214899; DOI=10.1016/j.febslet.2010.03.005;
RA   Kushnir A., Betzenhauser M.J., Marks A.R.;
RT   "Ryanodine receptor studies using genetically engineered mice.";
RL   FEBS Lett. 584:1956-1965(2010).
RN   [11]
RP   SUBUNIT.
RX   PubMed=28740084; DOI=10.1038/s41598-017-06395-6;
RA   Benson M.A., Tinsley C.L., Waite A.J., Carlisle F.A., Sweet S.M.M.,
RA   Ehler E., George C.H., Lai F.A., Martin-Rendon E., Blake D.J.;
RT   "Ryanodine receptors are part of the myospryn complex in cardiac muscle.";
RL   Sci. Rep. 7:6312-6312(2017).
RN   [12]
RP   MUTAGENESIS OF ASP-4645.
RX   PubMed=33536282; DOI=10.1126/scitranslmed.aba7287;
RA   Sun B., Yao J., Ni M., Wei J., Zhong X., Guo W., Zhang L., Wang R.,
RA   Belke D., Chen Y.X., Lieve K.V.V., Broendberg A.K., Roston T.M.,
RA   Blankoff I., Kammeraad J.A., von Alvensleben J.C., Lazarte J.,
RA   Vallmitjana A., Bohne L.J., Rose R.A., Benitez R., Hove-Madsen L.,
RA   Napolitano C., Hegele R.A., Fill M., Sanatani S., Wilde A.A.M.,
RA   Roberts J.D., Priori S.G., Jensen H.K., Chen S.R.W.;
RT   "Cardiac ryanodine receptor calcium release deficiency syndrome.";
RL   Sci. Transl. Med. 13:0-0(2021).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-217, AND MUTAGENESIS OF ALA-77
RP   AND VAL-186.
RX   PubMed=19913485; DOI=10.1016/j.str.2009.08.016;
RA   Lobo P.A., Van Petegem F.;
RT   "Crystal structures of the N-terminal domains of cardiac and skeletal
RT   muscle ryanodine receptors: insights into disease mutations.";
RL   Structure 17:1505-1514(2009).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-217.
RX   PubMed=21645850; DOI=10.1016/j.str.2011.03.016;
RA   Lobo P.A., Kimlicka L., Tung C.C., Van Petegem F.;
RT   "The deletion of exon 3 in the cardiac ryanodine receptor is rescued by
RT   beta strand switching.";
RL   Structure 19:790-798(2011).
RN   [15] {ECO:0007744|PDB:4ETV}
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 2699-2904.
RX   PubMed=22705209; DOI=10.1016/j.str.2012.04.015;
RA   Yuchi Z., Lau K., Van Petegem F.;
RT   "Disease mutations in the ryanodine receptor central region: crystal
RT   structures of a phosphorylation hot spot domain.";
RL   Structure 20:1201-1211(2012).
RN   [16] {ECO:0007744|PDB:2MC2, ECO:0007744|PDB:4KEI, ECO:0007744|PDB:4KEJ, ECO:0007744|PDB:4KEK}
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 1-217, AND DISULFIDE BONDS.
RX   PubMed=23978697; DOI=10.1016/j.jmb.2013.08.015;
RA   Amador F.J., Kimlicka L., Stathopulos P.B., Gasmi-Seabrook G.M.,
RA   Maclennan D.H., Van Petegem F., Ikura M.;
RT   "Type 2 ryanodine receptor domain A contains a unique and dynamic alpha-
RT   helix that transitions to a beta-strand in a mutant linked with a heritable
RT   cardiomyopathy.";
RL   J. Mol. Biol. 425:4034-4046(2013).
RN   [17] {ECO:0007744|PDB:5C33}
RP   X-RAY CRYSTALLOGRAPHY (1.21 ANGSTROMS) OF 650-844.
RX   PubMed=26245150; DOI=10.1038/ncomms8947;
RA   Yuchi Z., Yuen S.M., Lau K., Underhill A.Q., Cornea R.L., Fessenden J.D.,
RA   Van Petegem F.;
RT   "Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains
RT   reveal a critical FKBP12 binding determinant.";
RL   Nat. Commun. 6:7947-7947(2015).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm and thereby plays a key role
CC       in triggering cardiac muscle contraction. Aberrant channel activation
CC       can lead to cardiac arrhythmia. In cardiac myocytes, calcium release is
CC       triggered by increased Ca(2+) levels due to activation of the L-type
CC       calcium channel CACNA1C. The calcium channel activity is modulated by
CC       formation of heterotetramers with RYR3. Required for cellular calcium
CC       ion homeostasis. Required for embryonic heart development.
CC       {ECO:0000269|PubMed:10473538, ECO:0000269|PubMed:20431056,
CC       ECO:0000269|PubMed:21098440, ECO:0000269|PubMed:9628868}.
CC   -!- ACTIVITY REGULATION: Channel activity is modulated by the alkaloid
CC       ryanodine that binds to the open Ca-release channel with high affinity.
CC       At low concentrations, ryanodine maintains the channel in an open
CC       conformation. High ryanodine concentrations inhibit channel activity.
CC       Channel activity is regulated by calmodulin (CALM). The calcium release
CC       is activated by increased cytoplasmic calcium levels, by nitric oxyde
CC       (NO), caffeine and ATP. Channel activity is inhibited by magnesium
CC       ions, possibly by competition for calcium binding sites (By
CC       similarity). {ECO:0000250|UniProtKB:P11716}.
CC   -!- SUBUNIT: Homotetramer. Can also form heterotetramers with RYR1 and
CC       RYR3. Interacts with CALM and S100A1; these interactions regulate
CC       channel activity. Identified in a complex composed of RYR2, FKBP1B, PKA
CC       catalytic subunit, PRKAR2A, AKAP6, and the protein phosphatases PP2A
CC       and PP1. Interacts directly with FKBP1B, PKA, PP1 and PP2A (By
CC       similarity). Interacts with FKBP1A and FKBP1B; these interactions may
CC       stabilize the channel in its closed state and prevent Ca(2+) leaks.
CC       Interacts with SELENON (By similarity). Identified in a complex,
CC       composed of FSD2, CMYA5 and RYR2 (PubMed:28740084).
CC       {ECO:0000250|UniProtKB:P30957, ECO:0000250|UniProtKB:Q92736,
CC       ECO:0000269|PubMed:10473538, ECO:0000269|PubMed:20431056,
CC       ECO:0000269|PubMed:21098440, ECO:0000269|PubMed:28740084}.
CC   -!- INTERACTION:
CC       E9Q401; Q6PHZ2: Camk2d; NbExp=2; IntAct=EBI-643628, EBI-2308458;
CC       E9Q401; Q9Z2I2: Fkbp1b; NbExp=3; IntAct=EBI-643628, EBI-6379859;
CC       E9Q401; Q8K4S1: Plce1; NbExp=2; IntAct=EBI-643628, EBI-6902760;
CC       E9Q401; E9Q401: Ryr2; NbExp=7; IntAct=EBI-643628, EBI-643628;
CC       E9Q401; P23327: HRC; Xeno; NbExp=3; IntAct=EBI-643628, EBI-9639760;
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000305|PubMed:10473538}; Multi-pass membrane protein
CC       {ECO:0000305|PubMed:10473538}. Membrane {ECO:0000305|PubMed:10473538};
CC       Multi-pass membrane protein {ECO:0000305|PubMed:10473538}. Sarcoplasmic
CC       reticulum {ECO:0000250|UniProtKB:P30957}. Note=The number of predicted
CC       transmembrane domains varies between orthologs, but both N-terminus and
CC       C-terminus seem to be cytoplasmic. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, lung, cerebellum and
CC       brain. Detected at lower levels in adrenal gland, stomach, thymus,
CC       esophagus and ovary. {ECO:0000269|PubMed:7621815,
CC       ECO:0000269|PubMed:7876312}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein resides in the
CC       cytoplasm. {ECO:0000305}.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2807 and Ser-2813 increases the open probability of the calcium
CC       channel. Phosphorylation is increased in failing heart, leading to
CC       calcium leaks and increased cytoplasmic Ca(2+) levels.
CC       {ECO:0000269|PubMed:17693412, ECO:0000269|PubMed:20431056,
CC       ECO:0000269|PubMed:21098440}.
CC   -!- PTM: Phosphorylation at Ser-2030 by PKA enhances the response to
CC       lumenal calcium. {ECO:0000269|PubMed:17693412}.
CC   -!- DISRUPTION PHENOTYPE: Embryonically lethal. Embryos die at about 10
CC       dpc, due to defects in heart tube development. Cardiac myotubes display
CC       enlarged rough endoplasmic reticulum and cytoplasmic vesicles that
CC       contain high levels of Ca(2+). {ECO:0000269|PubMed:9628868}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF295105; AAG34081.1; -; mRNA.
DR   EMBL; AC131329; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC159208; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CT010468; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CT572985; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB012003; BAA25137.1; -; Genomic_DNA.
DR   EMBL; X83933; CAA58785.1; -; mRNA.
DR   EMBL; D38217; BAA07392.1; -; mRNA.
DR   CCDS; CCDS49206.1; -.
DR   PIR; I48742; I48742.
DR   RefSeq; NP_076357.2; NM_023868.2.
DR   PDB; 2MC2; NMR; -; A=10-224.
DR   PDB; 3IM5; X-ray; 2.55 A; A/B=1-217.
DR   PDB; 3IM6; X-ray; 1.70 A; A=1-217.
DR   PDB; 3IM7; X-ray; 2.21 A; A=1-217.
DR   PDB; 3QR5; X-ray; 2.30 A; A/B=1-217.
DR   PDB; 4ETV; X-ray; 1.65 A; A/B=2699-2904.
DR   PDB; 4KEI; X-ray; 2.41 A; A=1-217.
DR   PDB; 4KEJ; X-ray; 2.55 A; A=1-217.
DR   PDB; 4KEK; X-ray; 2.15 A; A=1-217.
DR   PDB; 4L4H; X-ray; 2.00 A; A=1-547.
DR   PDB; 4L4I; X-ray; 2.15 A; A=1-547.
DR   PDB; 4P9I; X-ray; 1.34 A; A=1080-1253.
DR   PDB; 4P9L; X-ray; 1.44 A; A=1080-1253.
DR   PDB; 5C33; X-ray; 1.21 A; A/B=650-844.
DR   PDB; 5VSN; X-ray; 1.44 A; A=1084-1252.
DR   PDB; 6J6L; X-ray; 1.45 A; A/B=650-844.
DR   PDB; 6MM5; X-ray; 1.95 A; C=2799-2810.
DR   PDB; 6MM6; X-ray; 2.39 A; D/F=2699-2904.
DR   PDB; 6MM7; X-ray; 1.85 A; C/E=2699-2904.
DR   PDB; 6MM8; X-ray; 1.85 A; D=2699-2904.
DR   PDB; 6WOU; EM; 3.27 A; A/B/C/D=1-4966.
DR   PDB; 6WOV; EM; 5.10 A; A/B/C/D=1-4966.
DR   PDB; 7VML; EM; 3.30 A; A/B/C/D=1-4966.
DR   PDB; 7VMM; EM; 3.50 A; A/B/C/D=1-4966.
DR   PDB; 7VMN; EM; 3.50 A; A/B/C/D=1-4966.
DR   PDB; 7VMO; EM; 3.50 A; A/B/C/D=1-4966.
DR   PDB; 7VMP; EM; 3.50 A; A/B/C/D=1-4966.
DR   PDB; 7VMQ; EM; 3.70 A; A/B/C/D=1-4966.
DR   PDB; 7VMR; EM; 3.30 A; A/B/C/D=1-4966.
DR   PDB; 7VMS; EM; 3.80 A; A/B/C/D=1-4966.
DR   PDBsum; 2MC2; -.
DR   PDBsum; 3IM5; -.
DR   PDBsum; 3IM6; -.
DR   PDBsum; 3IM7; -.
DR   PDBsum; 3QR5; -.
DR   PDBsum; 4ETV; -.
DR   PDBsum; 4KEI; -.
DR   PDBsum; 4KEJ; -.
DR   PDBsum; 4KEK; -.
DR   PDBsum; 4L4H; -.
DR   PDBsum; 4L4I; -.
DR   PDBsum; 4P9I; -.
DR   PDBsum; 4P9L; -.
DR   PDBsum; 5C33; -.
DR   PDBsum; 5VSN; -.
DR   PDBsum; 6J6L; -.
DR   PDBsum; 6MM5; -.
DR   PDBsum; 6MM6; -.
DR   PDBsum; 6MM7; -.
DR   PDBsum; 6MM8; -.
DR   PDBsum; 6WOU; -.
DR   PDBsum; 6WOV; -.
DR   PDBsum; 7VML; -.
DR   PDBsum; 7VMM; -.
DR   PDBsum; 7VMN; -.
DR   PDBsum; 7VMO; -.
DR   PDBsum; 7VMP; -.
DR   PDBsum; 7VMQ; -.
DR   PDBsum; 7VMR; -.
DR   PDBsum; 7VMS; -.
DR   BMRB; E9Q401; -.
DR   SMR; E9Q401; -.
DR   BioGRID; 203046; 22.
DR   ComplexPortal; CPX-3137; Ryanodine 2 complex.
DR   IntAct; E9Q401; 66.
DR   MINT; E9Q401; -.
DR   STRING; 10090.ENSMUSP00000021750; -.
DR   MoonDB; E9Q401; Predicted.
DR   iPTMnet; E9Q401; -.
DR   PhosphoSitePlus; E9Q401; -.
DR   SwissPalm; E9Q401; -.
DR   jPOST; E9Q401; -.
DR   MaxQB; E9Q401; -.
DR   PaxDb; E9Q401; -.
DR   PeptideAtlas; E9Q401; -.
DR   ProteomicsDB; 260963; -.
DR   Antibodypedia; 3476; 246 antibodies from 31 providers.
DR   DNASU; 20191; -.
DR   Ensembl; ENSMUST00000021750.15; ENSMUSP00000021750.8; ENSMUSG00000021313.17.
DR   GeneID; 20191; -.
DR   KEGG; mmu:20191; -.
DR   UCSC; uc007pld.1; mouse.
DR   AGR; MGI:99685; -.
DR   CTD; 6262; -.
DR   MGI; MGI:99685; Ryr2.
DR   VEuPathDB; HostDB:ENSMUSG00000021313; -.
DR   eggNOG; KOG2243; Eukaryota.
DR   GeneTree; ENSGT00940000154906; -.
DR   HOGENOM; CLU_000040_2_0_1; -.
DR   InParanoid; E9Q401; -.
DR   OMA; HYEDTSD; -.
DR   OrthoDB; 3144451at2759; -.
DR   PhylomeDB; E9Q401; -.
DR   TreeFam; TF315244; -.
DR   Reactome; R-MMU-2672351; Stimuli-sensing channels.
DR   Reactome; R-MMU-5578775; Ion homeostasis.
DR   BioGRID-ORCS; 20191; 3 hits in 78 CRISPR screens.
DR   ChiTaRS; Ryr2; mouse.
DR   PRO; PR:E9Q401; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   RNAct; E9Q401; protein.
DR   Bgee; ENSMUSG00000021313; Expressed in myocardium of ventricle and 145 other tissues.
DR   ExpressionAtlas; E9Q401; baseline and differential.
DR   Genevisible; E9Q401; MM.
DR   GO; GO:0031672; C:A band; ISO:MGI.
DR   GO; GO:0034704; C:calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:MGI.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; ISO:MGI.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0043005; C:neuron projection; ISO:MGI.
DR   GO; GO:0005635; C:nuclear envelope; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0032991; C:protein-containing complex; ISO:MGI.
DR   GO; GO:0042383; C:sarcolemma; ISO:MGI.
DR   GO; GO:0030017; C:sarcomere; IDA:BHF-UCL.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IDA:MGI.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0030018; C:Z disc; IDA:MGI.
DR   GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; ISO:MGI.
DR   GO; GO:0015278; F:calcium-release channel activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:MGI.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0097159; F:organic cyclic compound binding; IPI:MGI.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; ISO:MGI.
DR   GO; GO:0034237; F:protein kinase A regulatory subunit binding; ISO:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0043621; F:protein self-association; IMP:UniProtKB.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IDA:MGI.
DR   GO; GO:0097110; F:scaffold protein binding; ISO:MGI.
DR   GO; GO:0043924; F:suramin binding; ISO:MGI.
DR   GO; GO:0097553; P:calcium ion transmembrane import into cytosol; IMP:MGI.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IMP:MGI.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0060402; P:calcium ion transport into cytosol; ISO:MGI.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; ISO:MGI.
DR   GO; GO:0060048; P:cardiac muscle contraction; ISO:MGI.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:MGI.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0071313; P:cellular response to caffeine; IDA:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IMP:BHF-UCL.
DR   GO; GO:0005513; P:detection of calcium ion; ISO:MGI.
DR   GO; GO:0003143; P:embryonic heart tube morphogenesis; IMP:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; IMP:MGI.
DR   GO; GO:0072599; P:establishment of protein localization to endoplasmic reticulum; ISO:MGI.
DR   GO; GO:0034220; P:ion transmembrane transport; ISO:MGI.
DR   GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; IMP:MGI.
DR   GO; GO:0071421; P:manganese ion transmembrane transport; ISO:MGI.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; ISO:MGI.
DR   GO; GO:1901896; P:positive regulation of ATPase-coupled calcium transmembrane transporter activity; ISO:MGI.
DR   GO; GO:0010460; P:positive regulation of heart rate; IMP:MGI.
DR   GO; GO:0051284; P:positive regulation of sequestering of calcium ion; ISO:MGI.
DR   GO; GO:0098735; P:positive regulation of the force of heart contraction; ISO:MGI.
DR   GO; GO:0086029; P:Purkinje myocyte to ventricular cardiac muscle cell signaling; IMP:BHF-UCL.
DR   GO; GO:0098910; P:regulation of atrial cardiac muscle cell action potential; ISO:MGI.
DR   GO; GO:0098904; P:regulation of AV node cell action potential; ISO:MGI.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; ISO:MGI.
DR   GO; GO:0010882; P:regulation of cardiac muscle contraction by calcium ion signaling; ISO:MGI.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; IGI:BHF-UCL.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISO:MGI.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL.
DR   GO; GO:0098907; P:regulation of SA node cell action potential; ISO:MGI.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; ISO:MGI.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISO:MGI.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0031000; P:response to caffeine; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; ISO:MGI.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0032026; P:response to magnesium ion; ISO:MGI.
DR   GO; GO:0014850; P:response to muscle activity; ISO:MGI.
DR   GO; GO:0035994; P:response to muscle stretch; ISO:MGI.
DR   GO; GO:0051775; P:response to redox state; ISO:MGI.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; ISO:MGI.
DR   GO; GO:0097050; P:type B pancreatic cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0086005; P:ventricular cardiac muscle cell action potential; IMP:BHF-UCL.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 3.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF7; RYANODINE RECEPTOR 2; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 2.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Calcium channel; Calcium transport;
KW   Calmodulin-binding; Developmental protein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Phosphoprotein; Reference proteome;
KW   Repeat; Sarcoplasmic reticulum; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..4966
FT                   /note="Ryanodine receptor 2"
FT                   /id="PRO_0000415582"
FT   TOPO_DOM        1..4231
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4232..4252
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4278..4298
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4502..4522
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4579..4599
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4729..4749
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4768..4788
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        4819..4828
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        4849..4869
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        4870..4966
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          110..165
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          172..217
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          225..280
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          286..343
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          351..408
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          599..809
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          853..966
FT                   /note="1"
FT   REPEAT          967..1080
FT                   /note="2"
FT   DOMAIN          1025..1222
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   DOMAIN          1357..1563
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          2691..2809
FT                   /note="3"
FT   REPEAT          2811..2924
FT                   /note="4"
FT   REGION          853..2924
FT                   /note="4 X approximate repeats"
FT   REGION          1358..1377
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1857..1890
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2353..2372
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3580..3609
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000250"
FT   REGION          4335..4363
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4417..4466
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1859..1890
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4343..4363
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1870
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B0LPN4"
FT   MOD_RES         2030
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:17693412"
FT   MOD_RES         2368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         2696
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B0LPN4"
FT   MOD_RES         2796
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         2807
FT                   /note="Phosphoserine; by CaMK2D and PKA"
FT                   /evidence="ECO:0000269|PubMed:20431056,
FT                   ECO:0000269|PubMed:21098440, ECO:0007744|PubMed:21183079"
FT   MOD_RES         2810
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         2813
FT                   /note="Phosphoserine; by CaMK2D"
FT                   /evidence="ECO:0000269|PubMed:21098440,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         2946
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MUTAGEN         77
FT                   /note="A->V: No change to global protein fold or protein
FT                   stability. Alters local protein folding."
FT                   /evidence="ECO:0000269|PubMed:19913485"
FT   MUTAGEN         186
FT                   /note="V->M: No change to global protein fold or protein
FT                   stability. Alters local protein folding."
FT                   /evidence="ECO:0000269|PubMed:19913485"
FT   MUTAGEN         2813
FT                   /note="S->A: Protects against tachycardia and subsequent
FT                   death due to heart failure."
FT                   /evidence="ECO:0000269|PubMed:21098440"
FT   MUTAGEN         2813
FT                   /note="S->D: Abolishes phosphorylation by CaMK2D. Tendency
FT                   to tachycardia and subsequent death due to heart failure."
FT                   /evidence="ECO:0000269|PubMed:21098440"
FT   MUTAGEN         4645
FT                   /note="D->A: Mutant mice show systolic arrhythmogenic
FT                   abnormalities. Spontaneous Ca(2+) release from the
FT                   sarcoplasmic reticulum in the heart is diminished."
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT   MUTAGEN         4819
FT                   /note="G->A: Strongly reduced calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4821
FT                   /note="R->A: No effect on calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4823
FT                   /note="G->A: Reduced calcium channel activity. Reduces
FT                   single channel conductance by 97%. No effect on ryaodine
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4824
FT                   /note="G->A: No effect on calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4825
FT                   /note="G->A: Strongly reduced calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4827
FT                   /note="G->A: No effect on calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   MUTAGEN         4828
FT                   /note="D->A: No effect on calcium channel activity.
FT                   Abolishes ryanodine binding."
FT                   /evidence="ECO:0000269|PubMed:10473538"
FT   CONFLICT        1332
FT                   /note="N -> S (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1412
FT                   /note="D -> G (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1962
FT                   /note="R -> K (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2265
FT                   /note="V -> VA (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2532
FT                   /note="P -> R (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3192
FT                   /note="A -> T (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3533
FT                   /note="L -> F (in Ref. 1; AAG34081)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4324
FT                   /note="I -> T (in Ref. 4; CAA58785)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4853
FT                   /note="V -> E (in Ref. 4; CAA58785)"
FT                   /evidence="ECO:0000305"
FT   STRAND          15..17
FT                   /evidence="ECO:0007829|PDB:4KEJ"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          31..38
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          41..43
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   TURN            53..57
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          67..73
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   HELIX           75..84
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          97..102
FT                   /evidence="ECO:0007829|PDB:3QR5"
FT   STRAND          118..123
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   TURN            124..126
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          129..132
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          145..151
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          154..156
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          159..167
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          180..185
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   TURN            186..188
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          191..196
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          198..208
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   STRAND          212..216
FT                   /evidence="ECO:0007829|PDB:3IM6"
FT   HELIX           220..222
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          233..238
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   TURN            239..242
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          243..246
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           265..269
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          275..280
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   TURN            283..286
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          294..299
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   TURN            300..302
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          305..308
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          314..317
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           324..327
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          329..333
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   TURN            356..358
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          360..365
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   TURN            366..368
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          371..374
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          389..396
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          403..407
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           410..436
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           449..462
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           472..491
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           494..505
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          508..510
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           511..518
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   HELIX           520..541
FT                   /evidence="ECO:0007829|PDB:4L4H"
FT   STRAND          653..658
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          672..681
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          693..699
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   HELIX           700..702
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          704..706
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   HELIX           707..709
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          710..712
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          724..727
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          729..734
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          737..740
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          754..760
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   TURN            761..764
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          765..770
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          788..794
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          799..803
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   HELIX           822..825
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          833..839
FT                   /evidence="ECO:0007829|PDB:5C33"
FT   STRAND          1086..1089
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   HELIX           1092..1094
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1096..1109
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1111..1118
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1130..1138
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   TURN            1139..1142
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1143..1153
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1161..1167
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   TURN            1168..1171
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1172..1177
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1191..1194
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1201..1207
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   STRAND          1213..1216
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   HELIX           1221..1223
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   TURN            1227..1235
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   HELIX           1239..1242
FT                   /evidence="ECO:0007829|PDB:4P9I"
FT   HELIX           2714..2716
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2717..2737
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   TURN            2748..2751
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2754..2756
FT                   /evidence="ECO:0007829|PDB:6MM6"
FT   HELIX           2759..2761
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2764..2783
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   STRAND          2787..2790
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   STRAND          2792..2795
FT                   /evidence="ECO:0007829|PDB:6MM8"
FT   HELIX           2796..2799
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2811..2816
FT                   /evidence="ECO:0007829|PDB:6MM7"
FT   HELIX           2817..2819
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2827..2829
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2834..2861
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2873..2875
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   HELIX           2878..2897
FT                   /evidence="ECO:0007829|PDB:4ETV"
FT   STRAND          2900..2903
FT                   /evidence="ECO:0007829|PDB:4ETV"
SQ   SEQUENCE   4966 AA;  564819 MW;  F43425091AF7114F CRC64;
     MADAGEGEDE IQFLRTDDEV VLQCTATIHK EQQKLCLAAE GFGNRLCFLE STSNSKNVPP
     DLSICTFVLE QSLSVRALQE MLANTVEKSE GQVDVEKWKF MMKTAQGGGH RTLLYGHAIL
     LRHSYSGMYL CCLSTSRSST DKLAFDVGLQ EDTTGEACWW TIHPASKQRS EGEKVRVGDD
     LILVSVSSER YLHLSYGNSS WHVDAAFQQT LWSVAPISSG SEAAQGYLIG GDVLRLLHGH
     MDECLTVPSG EHGEEQRRTV HYEGGAVSVH ARSLWRLETL RVAWSGSHIR WGQPFRLRHV
     TTGKYLSLME DKNLLLMDKE KADVKSTAFA FRSSKEKLDV GVRKEVDGMG TSEIKYGDSI
     CYIQHVDTGL WLTYQAVDVK SARMGSIQRK AIMHHEGHMD DGLNLSRSQH EESRTARVIR
     STVFLFNRFI RGLDALSKKV KLPTIDLPIE SVSLSLQDLI GYFHPPDEHL EHEDKQNRLR
     ALKNRQNLFQ EEGMINLVLE CIDRLHVYSS AAHFADVAGR EAGESWKSIL NSLYELLAAL
     IRGNRKNCAQ FSGSLDWLIS RLERLEASSG ILEVLHCVLV ESPEALNIIK EGHIKSIISL
     LDKHGRNHKV LDVLCSLCVC HGVAVRSNQH LICDNLLPGR DLLLQTRLVN HVSSMRPNIF
     LGVSEGSAQY KKWYYELMVD HTEPFVTAEA THLRVGWAST EGYSPYPGGG EEWGGNGVGD
     DLFSYGFDGL HLWSGCIART VSSPNQHLLR TDDVISCCLD LSAPSISFRI NGQPVQGMFE
     NFNIDGLFFP VVSFSAGIKV RFLLGGRHGE FKFLPPPGYA ACYEAVLPKE KLKVEHSREY
     KQERTYTRDL LGPTVSLTQA AFTPVPVDTS QIVLPPHLER IRERLAENIH ELWVMNKIEL
     GWQYGPVRDD NKRQHPCLVE FCKLPEQERN YNLQMSLETL KTLLALGCHV GIADEHAEEK
     VKKMKLPKNY QLTSGYKPAP MDLSFIKLTP SQEAMVDKLA ENAHNVWARD RIRQGWTYGI
     QQDVKNRRNP RLVPYTLLDD RTKKSNKDSL REAVRTLLGY GYHLEAPDQD HASRAEVCSG
     TGERFRIFRA EKTYAVKAGR WYFEFEAVTA GDMRVGWSRP GCQPDLELGS DDRAFAFDGF
     KAQRWHQGNE HYGRSWQAGD VVGCMVDMNE HTMMFTLNGE ILLDDSGSEL AFKDFDVGDG
     FIPVCSLGVA QVGRMNFGKD VSTLKYFTIC GLQEGYEPFA VNTNRDITMW LSKRLPQFLQ
     VPSNHEHIEV TRIDGTIDSS PCLKVTQKSF GSQNNNTDIM FYRLSMPIEC AEVFSKSVAG
     GLPGAGFYGP KNDLEDFDVD SDFEVLMKTA HGHLVPDRID KDKETPKPEF NNHKDYAQEK
     PSRLKQRFLL RRTKPDYSTG HSARLTEDVL ADDRDDYEYL MQTSTYYYSV RIFPGQEPAN
     VWVGWITSDF HQYDTGFDLD RVRTVTVTLG DEKGKVHESI KRSNCYMVCA GESMSPGQGR
     NNSNGLEIGC VVDAASGLLT FIANGKELST YYQVEPSTKL FPAVFAQATS PNVFQFELGR
     IKNVMPLSAG LFKSEHKNPV PQCPPRLHVQ FLSHVLWSRM PNQFLKVDVS RISERQGWLV
     QCLDPLQFMS LHIPEENRSV DILELTEQEE LLQFHYHTLR LYSAVCALGN HRVAHALCSH
     VDEPQLLYAI ENKYMPGLLR AGYYDLLIDI HLSSYATARL MMNNEFIVPM TEETKSITLF
     PDENKKHGLP GIGLSTSLRP RMRFSSPSFV SISNDCYQYS PEFPLDILKA KTIQMLTEAV
     KEGSLHARDP VGGTTEFLFV PLIKLFYTLL IMGIFHNEDL KHILQLIEPS VFKEAAVPEE
     EGGTPEKEIS IEDAKLEGEE EAKGGKRPKE GLLQMKLPEP VKLQMCLLLQ YLCDCQVRHR
     IEAIVAFSDD FVAKLQDNQR FRYNEVMQAL NMSAALTARK TREFRSPPQE QINMLLNFKD
     DKSECPCPEE IRDQLLDFHE DLMTHCGIEL DEDGSLDGSN DLTIRGRLLS LVEKVTYLKK
     KQAEKPVASD SRKCSSLQQL ISETMVRWAQ ESVIEDPELV RAMFVLLHRQ YDGIGGLVRA
     LPKTYTINGV SVEDTINLLA SLGQIRSLLS VRMGKEEEKL MIRGLGDIMN NKVFYQHPNL
     MRALGMHETV MEVMVNVLGG GESKEITFPK MVANCCRFLC YFCRISRQNQ KAMFDHLSYL
     LENSSVGLAS PAMRGSTPLD VAAASVMDNN ELALALREPD LEKVVRYLAG CGLQSCQMLV
     SKGYPDIGWN PVEGERYLDF LRFAVFCNGE SVEENANVVV RLLIRRPECF GPALRGEGGN
     GLLAAMEEAI KIAEDPSRDG PSPTSGSSKT LDIEEEEDDT IHMGNAIMTF YAALIDLLGR
     CAPEMHLIHA GKGEAIRIRS ILRSLIPLGD LVGVISIAFQ MPTIAKDGKV VEPDMSAGFC
     PDHKAAMVLF LDRVYGIEVQ DFLLHLLEVG FLPDLRAAAS LDTAALSATD MALALNRYLC
     TAVLPLLTRC APLFAGTEHH ASLIDSLLHT VYRLSKGCSL TKAQRDSIEV CLLSICGQLR
     PSMMQHLLRR LVFDVPLLNE HAKMPLKLLT NHYERCWKYY CLPGGWGNFG AASEEELHLS
     RKLFWGIFDA LSQKKYEQEL FKLALPCLSA VAGALPPDYM ESNYVSMMEK QSSMDSEGNF
     NPQPVDTSNI TIPEKLEYFI NKYAEHSHDK WSMDKLANGW IYGEIYSDSS KIQPLMKPYK
     LLSEKEKEIY RWPIKESLKT MLAWGWRIER TREGDSMALY NRTRRISQTS QVSIDAAHGY
     SPRAIDMSNV TLSRDLHAMA EMMAENYHNI WAKKKKLELE SKGGGNHPLL VPYDTLTAKE
     KAKDREKAQD IFKFLQISGY VVSRGFKDLD LDTPSIEKRF AYSFLQQLIR YVDEAHQYIL
     EFDGGSRSKG EHFPYEQEIK FFAKVVLPLI DQYFKNHRLY FLSAASRPLC TGGHASNKEK
     EMVTSLFCKL GVLVRHRISL FGNDATSIVN CLHILGQTLD ARTVMKTGLD SVKSALRAFL
     DNAAEDLEKT MENLKQGQFT HTRSQPKGVT QIINYTTVAL LPMLSSLFEH IGQHQFGEDL
     ILEDVQVSCY RILTSLYALG TSKSIYVERQ RSALGECLAA FAGAFPIAFL ETHLDKHNVY
     SIYNTRSSRE RAALSLPANV EDVCPNIPSL EKLMTEIIEL AESGIRYTQM PYMMEVVLPM
     LCSYMSRWWE HGPENHPERA EMCCTALNSE HMNTLLGNIL KIIYNNLGID EGAWMKRLAV
     FSQPIINKVK PQLLKTHFLP LMEKLKKKAA MVVSEEDHLK AEARGDMSEA ELLILDEFTT
     LARDLYAFYP LLIRFVDYNR AKWLKEPNPE AEELFRMVAE VFIYWSKSHN FKREEQNFVV
     QNEINNMSFL ITDTKSKMSK AAISDQERKK MKRKGDRYSM QTSLIVAALK RLLPIGLNIC
     APGDQELIAL AKNRFSLKDT EEEVRDIIRS NIHLQGKLED PAIRWQMALY KDLPNRTEDP
     SDPERTVERV LGIANVLFHL EQKSKYTGRG YFSLVEHPQR SKKAVWHKLL SKQRKRAVVA
     CFRMAPLYNL PRHRAVNLFL QGYEKSWIET EEHYFEDKLI EDLAKPGAEL PEEDEAMKRV
     DPLHQLILLF SRTALTEKCK LEEDFLYMAY ADIMAKSCHD EEDDDGEEEV KSFEEKEMEK
     QKLLYQQARL HDRGAAEMVL QTISASKGET GPMVAATLKL GIAILNGGNS TVQQKMLDYL
     KEKKDVGFFQ SLAGLMQSCS VLDLNAFERQ NKAEGLGMVT EEGSGEKVLQ DDEFTCDLFR
     FLQLLCEGHN SDFQNYLRTQ TGNNTTVNII ISTVDYLLRV QESISDFYWY YSGKDIIDEQ
     GQRNFSKAIQ VAKQVFNTLT EYIQGPCTGN QQSLAHSRLW DAVVGFLHVF AHMQMKLSQD
     SSQIELLKEL MDLQKDMVVM LLSMLEGNVV NGTIGKQMVD MLVESSNNVE MILKFFDMFL
     KLKDLTSSDT FKEYDPDGKG VISKRDFHKA MESHKHYTQS ETEFLLSCAE TDENETLDYE
     EFVKRFHEPA KDIGFNVAVL LTNLSEHMPN DTRLQTFLEL AESVLNYFQP FLGRIEIMGS
     AKRIERVYFE ISESSRTQWE KPQVKESKRQ FIFDVVNEGG EKEKMELFVN FCEDTIFEMQ
     LAAQISESDL NERLANKEES EKERPEEQAP RMGFFSLLTI QSALFALRYN VLTLVRMLSL
     KSLKKQMKRM KKMTVKDMVL AFFSSYWSVF VTLLHFVASV CRGFFRIVSS LLLGGSLVEG
     AKKIKVAELL ANMPDPTQDE VRGDEEEGER KPLESALPSE DLTDLKELTE ESDLLSDIFG
     LDLKREGGQY KLIPHNPNAG LSDLMTNPVP VPEVQEKFQE QKAKEEKEEK EETKSEPEKA
     EGEDGEKEEK AKDEKSKQKL RQLHTHRYGE PEVPESAFWK KIIAYQQKLL NYFARNFYNM
     RMLALFVAFA INFILLFYKV STSSVVEGKE LPTRTSSDTA KVTNSLDSSP HRIIAVHYVL
     EESSGYMEPT LRILAILHTI ISFFCIIGYY CLKVPLVIFK REKEVARKLE FDGLYITEQP
     SEDDIKGQWD RLVINTQSFP NNYWDKFVKR KVMDKYGEFY GRDRISELLG MDKAALDFSD
     AREKKKPKKD SSLSAVLNSI DVKYQMWKLG VVFTDNSFLY LAWYMTMSVL GHYNNFFFAA
     HLLDIAMGFK TLRTILSSVT HNGKQLVLTV GLLAVVVYLY TVVAFNFFRK FYNKSEDGDT
     PDMKCDDMLT CYMFHMYVGV RAGGGIGDEI EDPAGDEYEI YRIIFDITFF FFVIVILLAI
     IQGLIIDAFG ELRDQQEQVK EDMETKCFIC GIGNDYFDTV PHGFETHTLQ EHNLANYLFF
     LMYLINKDET EHTGQESYVW KMYQERCWEF FPAGDCFRKQ YEDQLN
//
